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Abstract
Background: Mycobacterium tuberculosis complex (MTBC), the causative agent of tuberculosis (TB), is characterized by low
sequence diversity making this bacterium one of the classical examples of a genetically monomorphic pathogen. Because of
this limited DNA sequence variation, routine genotyping of clinical MTBC isolates for epidemiological purposes relies on
highly discriminatory DNA fingerprinting methods based on mobile and repetitive genetic elements. According to the
standard view, isolates exhibiting the same fingerprinting pattern are considered direct progeny of the same bacterial clone,
and most likely reflect ongoing transmission or disease relapse within individual patients.
Methodology/Principal Findings: Here we further investigated this assumption and used massively parallel whole-genome
sequencing to compare one drug-susceptible (K-1) and one multidrug resistant (MDR) isolate (K-2) of a rapidly spreading M.
tuberculosis Beijing genotype clone from a high incidence region (Karakalpakstan, Uzbekistan). Both isolates shared the
same IS6110 RFLP pattern and the same allele at 23 out of 24 MIRU-VNTR loci. We generated 23.9 million (K-1) and 33.0
million (K-2) paired 50 bp purity filtered reads corresponding to a mean coverage of 483.5 fold and 656.1 fold respectively.
Compared with the laboratory strain H37Rv both Beijing isolates shared 1,209 SNPs. The two Beijing isolates differed by 130
SNPs and one large deletion. The susceptible isolate had 55 specific SNPs, while the MDR variant had 75 specific SNPs,
including the five known resistance-conferring mutations.
Conclusions: Our results suggest that M. tuberculosis isolates exhibiting identical DNA fingerprinting patterns can harbour
substantial genomic diversity. Because this heterogeneity is not captured by traditional genotyping of MTBC, some aspects
of the transmission dynamics of tuberculosis could be missed or misinterpreted. Furthermore, a valid differentiation
between disease relapse and exogenous reinfection might be impossible using standard genotyping tools if the overall
diversity of circulating clones is limited. These findings have important implications for clinical trials of new anti-tuberculosis
drugs.
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Introduction
Tuberculosis (TB) is primarily a symptom of poverty and
inequality [1,2], which accounts for its uninterrupted prevalence
in most parts of the world [3]. This disparity in TB burden is
further exacerbated by the widespread emergence of antibiotic
resistance [4]. In Eastern Europe, all of these factors coincide. In
Karakalpakstan (Uzbekistan) multi-drug resistant (MDR) Mycobac-
terium tuberculosis complex (Mtb) strains infect up to 22% of patients
never treated and up to 60% of those previously treated [3,4,5].
Therefore the most effective antibiotics with the fewest side-effects,
isoniazid (INH) and rifampicin (RMP), must, in MDR TB, be
replaced by less-effective, more expensive, and more toxic
substitutes.
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7407In addition to the socio-economic, environmental, and host
genetic determinants [6], strain genetic diversity in Mtb appears to
play a more important role than previously believed [7,8,9,10].
Mtb comprises several phylogenetic lineages, some of which have
been shown to significantly impact progression from infection to
active tuberculosis as well as disease manifestation [11,12,13]. In
Karakalpakstan and other parts of Eastern Europe, the so-called
Beijing lineage of Mtb is mostly responsible for the ongoing MDR
epidemic [14]. Some members of this strain lineage have been
reported to be hypervirulent in animal models [15], and others
have been associated with large outbreaks and extensive
transmission of MDR TB in various regions of the world
[7,16,17]. These findings contradict previous assumptions that
resistant Mtb strains in general have a reduced fitness. The fact
that MDR variants can even have an enhanced fitness when
compared with susceptible progenitor strains, points to the
phenomenon of compensatory evolution that can reverse adverse
effects on bacterial fitness [18,19].
Even though genetic diversity appears to influence virulence
and immunogenicity of strain of different phylogenetic lineages
[9], the overall level of sequence variation in Mtb is low and Mtb is
considered to represent the ‘‘upper limit of what might be
considered genetically monomorphic’’ [20]. Whole genome
comparisons of M. tuberculosis and M. bovis, another species of the
M. tuberculosis complex, revealed a maximum diversity of just 2,500
SNPs [21]. M. tuberculosis isolates of the same clone or strain (e.g.
characterised by IS6110 genotyping) are generally considered to
be identical and belong to the same outbreak or recent chain of
transmission [22]. However, the real level of genomic diversity in
rapidly expanding clones from high incidence settings has not been
assessed.
To address this question, we have applied massively paralleled
whole-genome sequencing [23] to two clinical isolates from
Karakalpakstan. These isolates were virtually identical with
respect to all standard TB genotyping markers, including IS6110
RFLP, which is the most discriminating test of all standard
molecular TB typing tools in use today [22] (Figure 1). The two
isolates, K-1 and K-2, differed in only 1 of 24 Mycobacterial
Interspersed Repetitive Units. However, whilst K-1 was fully drug-
susceptible, K-2 was resistant to all first line drugs (INH, RMP,
ethambutol (EMB), pyrazinamide (PZA) and streptomycin (SM)).
Both isolates were part of a large cluster of closely related
organisms termed the Beijing K-family that encompasses the
dominant, expanding Mtb variant in the region [unpublished
results,14].
Results
Genome coverage
We generated 23.9 million (K-1) and 33.0 million (K-2) paired
50 bp purity filtered reads corresponding to a mean coverage of
483.5 fold and 656.1 fold respectively which we compared to the
genome of the M. tuberculosis reference strain H37Rv (ATCC
27294) [24]. To differentiate true differences from sequencing
errors in the original H37Rv reference sequence (File S1), we also
generated 2.7 Gb of sequence data from strain H37Rv (26.7
million paired 50 bp reads, 538.5-fold coverage). The fraction of
the H37Rv genome that could not be covered (approximately
2.0%) comprised DNA with a GC content .80% and repeat
regions (such as IS6110 elements) whose sequence could not be
uniquely aligned to the reference. This fraction increased to 4.8%
for K-1 and 3.4% for K-2 to exclude any areas for which no valid
base was called due to insertion or deletions. All the genetic
changes we identified are correlated with the existing scientific
literature and listed in detail in the Supplementary Information
(File S1). In addition to a tabular output of our results (File S2) a
flexible, graphical representation using Artemis [25] is provided
(Files S3-S6) to allow an exploration of these changes in their
genomic context.
Errors in reference genome
Re-sequencing of H37Rv uncovered 80 SNPs with respect to
the published reference genome. 74 SNPs were shared with the
Beijing isolates sequenced in this study (Figure 2A), all of which
were also detected in one or more studies of H37Ra, the avirulent
form of H37 (File S1), by the following different experimen-
tal methodologies: a microarray-based comparative approach
[26], re-sequencing [27] and a complete genome sequence
(CP000611.1) from a shotgun library [28]. In contrast, the 6
H37Rv specific SNPs did not feature in any of these studies. Re-
examination of the electropherograms of the original H37Rv
sequence revealed that 44 of these SNPs were errors in the
reference strain H37Rv data (File S1). The remaining differences
might represent micro-evolutionary events that occurred while
culturing of the different H37 variants in separate laboratories.
Figure 1. Genotyping and drug resistance data of the strains analysed. All traditional DNA fingerprints for both isolates were isogenic, with
the exception of the MIRU-VNTR locus 1955. K-2 was resistant to all five first line antibiotics (S (sensitive), R (resistant)).
doi:10.1371/journal.pone.0007407.g001
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PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7407Figure 2. Overview of the genome data obtained. A, Venn diagram showing the SNP distribution between the three genomes under
investigation (H37Rv, K-1, and K-2) relative to the published H37Rv sequence. The 75 K-2 specific SNPs encompassed the 5 resistance conferring SNPs
(Table 2). 44 of the 74 SNPs shared in the three genomes were found to be errors in the H37Rv reference (File S1). B, Summary of nature and location
of SNPs detected in this study. C, Circular plot of H37Rv reference genome prepared with DNAPlotter [46]. The two outer-most circles show the genes
on the forward and reverse strand respectively with the annotation and colour coding derived from TubercuList [47]. The remaining 5 internal circles
correspond to the 5 filled subsection of the Venn diagram in Figure 2A with identical colour coding (from third to inner-most circle: SNPs common to
all 3 genomes; Beijing K-family backbone SNPs; K-1, K-2 and H37Rv specific SNPs). Non-synonymous or inter-genic SNPs are shown as long lines
whereas short lines represent synonymous SNPs. In two cases, where a SNP was non-synonymous in one gene and synonymous in a second,
overlapping gene intermediate lines were used. The 5 resistance causing mutations in K-2 (Table 2) are highlighted separately in red on the outside.
An equivalent, fully zoomable representation for each individual genome based on Artemis [25] is available in the Supplement (Files S3-S6).
doi:10.1371/journal.pone.0007407.g002
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Next, we compared K-1 and K-2 to H37Rv. Both Beijing
isolates shared a common pool of 1,209 single-nucleotide-
polymorphisms (SNPs) (Figure 2A) and five large scale deletions
compared to H37Rv (Table 1). These Beijing-specific differences
were congruent with a set of variants reported previously (File S1).
An overview about all previously described SNPs is given in File
S1. We found that the majority of the SNPs in K-1 and K-2 were
non-synonymous (57% in both cases), which confirms previous
findings [29] and is consistent with reduced purifying selection
acting on Mtb [10] (Figure 2B).
In addition to this common backbone of Beijing specific
variation, we identified 130 SNPs and one deletion that
differentiated K-1 and K-2 (Figure 2A and Figure 3), although
both isolates were identical with respect to IS6110 typing
(Figure 1). Compared to H37Rv, the susceptible isolate K-1
encoded 55 specific SNPs and one specific deletion, while the
MDR variant K-2 had 75 specific SNPs, including the five
resistance-conferring mutations in the katG, rpoB, embB, pncA, and
rpsL genes that are known to be altered in resistance to INH, RIF,
EMB, PZA, and SM, respectively [30] (Table 2, Figure 2C).
Importantly, the observed level of diversity was independent of the
MDR phenotype of K-2, as we detected comparable numbers of
SNPs in both the drug-susceptible K-1 and the MDR K-2.
We then investigated the diversity between different lineages.
Despite the fact that the total number of differences we observed
between the Beijing isolates K-1/K-2 and the laboratory strain
H37Rv was in the same range of the DNA variation described
earlier between H37Rv and the clinical strain CDC1551 [29], a
comparison to the whole genome sequences of CDC1551
(AE000516.2), F11 (CP000717.1) and M. bovis (BX248333.1)
revealed that more than half of the SNPs in K-1 were in fact
unique to the Beijing genotype (Figure 4).
Discussion
Early sequencing studies of M. tuberculosis showed an extremely
high level of clonality and conservation [31,32]. As a consequence,
standard molecular markers that are based on mobile or repetitive
elements (IS6110 RFLP, spoligotyping and MIRU-VNTR typing)
are presumed to provide a high enough discriminatory power to
accurately reconstruct transmission chains as part of epidemiolog-
ical studies. Based on these standard criteria, our isolates K-1 and
K-2 that exhibit the same molecular fingerprint can be considered
as belonging to the same ‘‘outbreak clone’’ that is rapidly
expanding in the study area by extensive transmission [22].
Therefore, we expected to find a low amount of genetic diversity.
By contrast, we observed a strikingly high genomic diversity
among two isolates sharing the same DNA fingerprint. These
findings challenge the ‘‘identical fingerprints – same strain’’ dogma
and have important implications for the investigation of disease
dynamics, especially in high incidence regions such as Eastern
Europe where the Beijing genotype is dominant and the
population diversity (e.g. among MDR strains) is significantly
reduced [unpublished results,14,33]. The fact that strains with
identical genotyping patterns can accumulate significant amounts
of genetic diversity indicates that epidemiological links between
isolates with identical genotyping data can be more remote and
are likely to represent older transmission events rather than cases
of recent transmission among patients in one RFLP cluster. Under
these circumstances, a valid differentiation of relapse and re-
infection, that can occur in significant numbers in TB patients
Table 1. Large chromosomal deletions detected in both
Beijing isolates K-1 and K-2 [57].
Name Genes Comment
RD105 Rv0071-Rv0074 robust Beijing marker
RD149 Rv1572c-Rv1587c occurs in all Beijing isolates
RD152 Rv1754c-Rv1762c occurs in all Beijing isolates
RD181 Rv2262c-Rv2263 variably deleted in Beijing isolates
RD207 Rv2816c-Rv2820c occurs in all Beijing isolates
doi:10.1371/journal.pone.0007407.t001
Figure 3. Genomic deletion specific for K-1. A, Graph showing the depth of coverage. A drop in coverage is visible in K-1 suggesting a deletion
relative to the H37Rv reference. B, PCR and subsequent dideoxy sequencing (data not shown) identified a K-1 specific deletion at 859244-859501
(257 bp) affecting cyp123 (Rv0766c) in correspondence with the coverage plot (Figure 3A).
doi:10.1371/journal.pone.0007407.g003
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[34], might not be possible by applying traditional genotyping.
One of the key objectives of molecular epidemiology in TB is to
distinguish treatment failure/relapse with the same strain from
exogenous reinfection with a second strain. This is particularly
important given the emergence of MDR and extensively-drug
resistant (XDR) TB in many parts of the world [4,35,36]. If a TB
patient fails treatment, this indicates that the infecting strain might
have become drug-resistant, or that the treatment is not effective,
for example because of a lack of patient compliance. In the case of
clinical trials where new TB drugs are being evaluated, treatment
failure may suggest poor drug performance. Large amounts of
resources are now being invested into the development of new
drugs against TB [3]. Some of these new drug candidates are
entering human trials. If during these trials treatment failures are
not adequately differentiated from cases of exogenous re-infection,
promising new drug candidates may be abandoned erroneously.
A large genetic diversity among closely related isolates of Mtb
has also implications for our understanding of the evolution of
drug resistance. A recent report detected only few differences
when comparing the genomes of MDR and XDR Mtb strains
from KwaZulu-Natal, South Africa to an isogenic drug-susceptible
isolate (11 unique SNPs in the MDR and 15 in the DS and XDR,
respectively) [37,38]; the authors concluded that the evolution of
drug resistance might be relatively easy to study [38]. We have
previously shown that the fitness of drug-resistant Mtb depends
both on the specific drug-resistance-conferring mutations and
strain genetic backgrounds, and that compensatory mutations
might mitigate the potential deleterious effects of drug resistance
on bacterial fitness [8,18]. Some of the strain specific mutations in
K-2 might represent mutations which are compensating for
putative fitness effects of the drug resistance-conferring mutations.
However, more work is needed to explore this possibility.
Finally, the high number of novel SNPs that are unique to the
Beijing lineage confirmed that previously sequenced genomes only
sampled a small part of the global diversity of Mtb [9]. These
findings highlight the importance of current sequencing efforts to
capture the full global diversity of Mtb to ensure that both
antibiotics and vaccines that are currently undergoing clinical
trials [3] are efficacious against all strains.
In conclusion, our results showed that genomic diversity in
closely related strains of Mtb may be greater than anticipated.
Clonal variants can accumulate high levels of genomic diversity,
which can lead to different pathogenic properties undetectable by
standard genotyping [27]. Methods to accurately index strain
diversity are essential for TB control, especially for the evaluation
of new drugs, diagnostics and vaccines. Whole genome sequencing
is likely to become available soon for routine molecular
epidemiology at comparable costs to traditional typing techniques
[39]. Instead of having to rely on molecular surrogates with a
limited resolution, such an approach would be highly informative
both by giving a more accurate picture of ongoing tuberculosis
transmission and related epidemiological outcomes such as re-
infection and mixed infections, as well as by shedding light on the
microevolutionary processes occurring in M. tuberculosis during
spread. In clinical settings, such an approach could allow for rapid
detection of drug-resistant TB and enhanced disease surveillance.
Methods
K-1 was isolated from sputum in 11/2001 and K-2 in 09/2004.
IS6110 RFLP fingerprints, spoligotype patterns and MIRU-
VNTR profiles were determined as previously described
[40,41,42,43]. Antibiotic resistance was determined with the
BACTEC MGIT 960 [44,45].
,200 bp paired read fragment libraries were prepared from
1 mg of DNA, and sequenced using the Illumina Genome
Analyzer as described previously [23]. SNPs were mapped by
paired short read alignment of individual reads to their cognate
positions in the M. tuberculosis H37Rv genome (AL123456.2) and
called at threshold $100 with the Illumina Genome Analyzer
Table 2. SNPs in K-2 responsible for antibiotic resistances.
Antibiotic Gene Synonym Position Base change Amino acid Reference
Isoniazid katG Rv1908c 2155168 aGc/aCc S315T [48,49]
a
Rifampicin rpoB Rv0667 761161 cTg/cCg L(s)452P
b [50]
Ethambutol embB Rv3795 4248003 cAg/cGg Q497R [51,52]
Pyrazinamide pncA Rv2043c 2288885 tgG/tgA W119* [53,54,55]
c
Streptomycin rpsL Rv0682 781687 aAg/aGg K43R [56]
aMutation leads to high level resistance.
bPlease note that this corresponds to amino acid 458 based on the TIGR annotation of H37Rv (http://cmr.jcvi.org/cgi-bin/CMR/GenomePage.cgi?org=ntmt02) in which
the N-terminus was annotated to start 6 amino acids upstream of the start in TubercuList. The equivalent amino acid in E. coli is 533.
cFor a detailed discussion of this mutation please refer to the Supplementary Results(File S1).
doi:10.1371/journal.pone.0007407.t002
Figure 4. Comparison of SNPs across Mtb genomes. Edwards’
Venn diagram showing the distribution of SNPs in K-1 (1,338 total) and
the published genomes of CDC1551 (1,114 total), F11 (833 total) and M.
bovis (2,294 total) relative to the published H37Rv sequence.
doi:10.1371/journal.pone.0007407.g004
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call was accepted when the ratio between the two calls was $3.
Only positions for which valid base calls were available in all
genomes were considered for our assessment of the diversity. The
validity of the SNP calls was confirmed by 40 kb of dideoxy chain
terminator sequencing (ABI 3130xl) of each isolate. Deletions
$250 bp were detected using combined paired read data and
localised homology mapping across the deletion boundary.
Details of the annotation used for the SNP analysis and the
graphical representation of the tabular results (File S2) with
Artemis [25] (Files S3-6) can be found in the Supplementary
Methods (File S1).
Supporting Information
File S1 Description of supplementary information Supplemen-
tary Tables and Figures as well as Supplementary Methods and
Results
Found at: doi:10.1371/journal.pone.0007407.s001 (1.07 MB
PDF)
File S2 Supplementary information - Excel file with all SNPs
detected
Found at: doi:10.1371/journal.pone.0007407.s002 (0.30 MB ZIP)
File S3 Contains the H37Rv genome (AL123456.2) and
TubercuList R11 annotation, necessary for the graphical repre-
sentation of all SNPs.
Found at: doi:10.1371/journal.pone.0007407.s003 (1.96 MB ZIP)
File S4 contains the graphical representation of SNPs in H37Rv
Found at: doi:10.1371/journal.pone.0007407.s004 (0.05 MB ZIP)
File S5 Contains the graphical representation of SNPs in K-1
(Section 2.2).
Found at: doi:10.1371/journal.pone.0007407.s005 (0.05 MB ZIP)
File S6 Contains the graphical representation of SNPs in K-2
(Section 2.2).
Found at: doi:10.1371/journal.pone.0007407.s006 (0.05 MB ZIP)
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